What’s available now and what’s on the horizon (Early development)

Brief Synopsis:

Antibody drug conjugates (ADCs), comprising of targeted antibodies conjugated to toxic payload, represent a new class of hybrid therapeutics (targeted therapy with chemotherapy). ADCs provide several advantages over traditional chemotherapy and there are a number of ADCs in clinical development. In this presentation, we will review the biological rationale, ongoing clinical development, and future therapeutic strategies for patients with metastatic breast cancer.